2-hydroxy-4-(2-propenyloxy)benzoic acid methyl ester | 79557-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-4-(2-propenyloxy)benzoic acid methyl ester
• 英文别名: 4-(allyloxy)-2-hydroxycarbomethoxybenzene；methyl 4-allyloxy-2-hydroxybenzoate；methyl 2-hydroxy-4-allyloxybenzoate；4-allyloxy-2-hydroxy-benzoic acid methyl ester；methyl 4-(allyloxy)-2-hydroxybenzoate；Methyl 2-hydroxy-4-[(prop-2-en-1-yl)oxy]benzoate；methyl 2-hydroxy-4-prop-2-enoxybenzoate
• CAS: 79557-58-7
• 化学式: C₁₁H₁₂O₄
• 分子量: 208.214
• InChiKey: SSHQSOPLZKHZHB-UHFFFAOYSA-N

物化性质

• 沸点：
  145-155 °C(Press: 7 Torr)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-hydroxy-4-(2-propenyloxy)benzoic acid methyl ester 在 palladium on activated charcoal 氢气 作用下， 生成 2,4-dihydroxy-3-propylbenzoic acid methyl ester
  参考文献：
  名称：

  Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

  摘要：

  Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 16 and 18). Although considerable attention has focused on FPL 55712-derived analogues, only limited investigations into alternatives for the standard 4-acetyl-3-hydroxy-2-propylphenoxy moiety have been reported. Therefore, an extensive study of modifications to the hydroxyacetophenone portion of toluic acid 18 was undertaken. Although no viable alternative to the 3-hydroxy moiety was discovered, replacements for the 2-propyl group (34, 37) and the 4-acetyl functionality (56, 59) yielded potent antagonists. A number of compounds exhibited longer duration of action in vivo than FPL 55712.

  DOI：

  10.1021/jm00124a014
• 作为产物：
  描述：

  2,4-二羟基苯甲酸甲酯 、 3-溴丙烯 在 potassium carbonate 作用下， 以 正己烷 、 乙酸乙酯 、 丙酮 为溶剂， 生成 2-hydroxy-4-(2-propenyloxy)benzoic acid methyl ester
  参考文献：
  名称：

  Leukotriene B.sub.4 antagonists

  摘要：

  本发明涉及式I的化合物及其立体异构体和药用可接受的盐，其中R为烷基、烯基、炔基或环烷基烷基；R.sup.1为烷基；R.sup.2为氢或烷基；R.sup.6为烷基；n为1至5；p为0至6；x为0或2；而R.sup.4和R.sup.5独立地为氢或烷基，或者与N一起形成环烷基胺。式I的化合物是白三烯B.sub.4拮抗剂，可用作抗炎药物，并用于治疗由LTB.sub.4介导的疾病症状。

  公开号：

  US05124350A1

文献信息

• Substituted aryloximes
  申请人：Havran Marie Lisa

  公开号：US20050070584A1

  公开（公告）日：2005-03-31

  The present invention relates to substituted aryl oximes and methods of using them.

  本发明涉及取代的芳香基氧化亚氮及其使用方法。
• Indole derivative having piperidine ring
  申请人：Suzuki Yuichi

  公开号：US20050256103A1

  公开（公告）日：2005-11-17

  The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.

  本发明涉及以下公式所代表的化合物，其药学上可接受的盐，或其作为药物的用途： 其中R1和R2是相邻的取代基，与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物，该基可能被1至4个取代基所取代，所述取代基选自（1）氧代基，（2）羟基等；R3代表氢原子或类似物；R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状，特别是涉及尿液储存的症状的药剂，该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
• Catechol carboxylic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US05025036A1

  公开（公告）日：1991-06-18

  The invention relates to catechol carboxylic acid derivatives of the formula ##STR1## wherein, R.sub.1 is ##STR2## acetyl, hydrogen, hydroxy or alkanoyloxy, R.sub.2 is ##STR3## hydroxy, hydrogen or alkanoyloxy, wherein R is hydrogen, lower alkyl or --(CH.sub.2).sub.n --N--(lower alkyl).sub.2, R.sub.3 is hydrogen, lower alkyl or amino, R.sub.4 is hydrogen, lower alkyl, halogen or amino A is ##STR4## wherein, R.sub.5 is hydrogen or acyl, R.sub.6 is hydrogen, halogen, lower alkyl, aryl or cycloalkyl, and R.sub.7 and R.sub.8, independently, are hydrogen, lower alkyl or halogen, or A is ##STR5## wherein, R.sub.5 is hydrogen or acyl, R.sub.9 is hydrogen, lower alkyl, R.sub.10 is hydrogen, lower alkyl or halogen, R.sub.11 is hydrogen, lower alkyl, cycloalkyl or halogen, m is 0 or 1, n is an integer of 2-10, provided, that no more than one of R.sub.1 or R.sub.2 can be hydroxy, alkanoyloxy or ##STR6## and when R is hydrogen, salts thereof with pharmaceutically acceptable bases or when R is --(CH.sub.2).sub.n --N--(lower alkyl).sub.2, salts thereof with pharmaceutically acceptable acids. The compounds of formula I are useful as agents for the treatment of inflammatory diseases such as arthritis, inflammatory bowel disease such as colitis, cardiovascular diseases such as myocardial ischemia, skin diseases such as psoriasis by topical administration, and bronchopulmonary diseases such as asthma.

  这项发明涉及公式##STR1##的儿茶酚羧酸衍生物，其中，R.sub.1为##STR2##乙酰基，氢，羟基或烷酰氧基，R.sub.2为##STR3##羟基，氢或烷酰氧基，其中R为氢，低烷基或--(CH.sub.2).sub.n --N--(低烷基).sub.2，R.sub.3为氢，低烷基或氨基，R.sub.4为氢，低烷基，卤素或氨基，A为##STR4##其中，R.sub.5为氢或酰基，R.sub.6为氢，卤素，低烷基，芳基或环烷基，而R.sub.7和R.sub.8，独立地，为氢，低烷基或卤素，或A为##STR5##其中，R.sub.5为氢或酰基，R.sub.9为氢，低烷基，R.sub.10为氢，低烷基或卤素，R.sub.11为氢，低烷基，环烷基或卤素，m为0或1，n为2-10的整数，前提是R.sub.1或R.sub.2中不超过一个可以是羟基，烷酰氧基或##STR6##，当R为氢时，其与药学上可接受的碱盐，或当R为--(CH.sub.2).sub.n --N--(低烷基).sub.2时，其与药学上可接受的酸盐。公式I的化合物可用作治疗类风湿性关节炎、炎症性肠病如结肠炎、心血管疾病如心肌缺血、皮肤疾病如牛皮癣经局部给药治疗，以及支气管肺部疾病如哮喘的药物。
• An investigation into the regioselectivity of the acid catalysed Claisen rearrangement of methyl 4- and 5-allyloxy-2-hydroxybenzoate and derivatives
  作者：Laurence M. Harwood

  DOI：10.1039/c39830000530

  日期：——

  The observed products from the acid catalysed Claisen rearrangement of the methyl esters (1c–g) indicate that, unlike the thermal reaction, regiochemical control is independent of internal hydrogen bonding.

  酸催化甲基酯的克莱森重排（1c – g）观察到的产物表明，与热反应不同，区域化学控制不受内部氢键的影响。
• Dihydroxynaphthalene derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04937371A1

  公开（公告）日：1990-06-26

  There are described dihydroxy naphthalene derivatives of the formula ##STR1## in which R.sub.1 is hydrogen, lower alkyl or benzyl, R.sub.2 is hydrogen, hydroxy or lower alkanoyloxy, R.sub.3 is hydrogen or lower alkyl, R.sub.4 is hydrogen or halogen, R.sub.5 is hydrogen, acyl, methyl or benzyl, m is 0 or 1, and n is an integer from 2 to 10, as well as salts thereof with pharmaceutically acceptable bases when R.sub.1 is hydrogen. These compounds are useful as agents for the treatment of inflammatory bowel diseases, for instance, colitis, as pro-drugs, or as intermediates for the preparation of such compounds.

  描述了公式为##STR1##的二羟基萘衍生物，其中R.sub.1是氢、较低的烷基或苄基，R.sub.2是氢、羟基或较低的烷酰氧基，R.sub.3是氢或较低的烷基，R.sub.4是氢或卤素，R.sub.5是氢、酰基、甲基或苄基，m为0或1，n为2到10的整数，以及其与药学上可接受的碱的盐，当R.sub.1是氢时。这些化合物可用作治疗炎症性肠病的药物，例如结肠炎，作为前药，或作为制备这类化合物的中间体。